Brandon BioCatalyst

Kinoxis Therapeutics closes $6.75 million financing round

Melbourne biotech Kinoxis completed a $6.75 million round with new backer MainSequence and won a $2.5 million government-funded CUREator+ grant for dementia and pain drug development; MainSequence's Elaine Stead joins the board.

Also Startup Daily·Startup Daily·Dealroom·This Week in Australian Startups·Dynamic Business

Dementia biotech Kinoxis raises $6.75 million with a $2.5m grant as cherry on top

Melbourne dementia drug developer Kinoxis secured $6.75 million equity led by Main Sequence plus a $2.5 million Medical Research Future Fund grant via CUREator+, funding trials of its agitation and pain drug candidates.

Denteric Pty Ltd – Vaccine for P. gingivalis-associated dementia

Profile of Denteric, a biotech developing GPV381, an injectable therapy targeting gum bacteria implicated in Alzheimer's disease; the team is seeking backers to fund its first study in patients.

Ceretas triggers final $490,000 grant tranche as dementia device prototypes clear review

Australian medtech Ceretas hit a milestone in its CUREator+ program, unlocking the final instalment of a government-funded grant; the piece also recaps its A$8 million IPO and ASX listing earlier in 2026.

Six biomedtech startups share $13.5 million in CUREator+ grants to fast-track health breakthroughs

Six Australian health tech startups received non-dilutive grants totaling $13.5 million from the government-backed CUREator+ program to accelerate commercialisation of medical innovations.

Brandon BioCatalyst's CUREator+ distributes $13.5M in grants

Six Australian biomedical and health ventures receive a combined $13.5 million in non-dilutive grants through round two of the CUREator+ commercialisation program operated by Brandon BioCatalyst and backed by the Medical Research Future Fund.

Also Dealroom

CUREator+ backs six Australian startups with $13.5 million to advance new health technologies

Six Australian health tech startups received a combined $13.5 million in non-dilutive funding from the CUREator+ program, supported by the Australian Government.

Kraken Coding: from hospital pharmacy to health-tech founder on a mission to help clinicians make faster, safer decisions

Interview with John Shanks, a former hospital pharmacist who founded Kraken Coding to turn clinical guidelines into digital decision-support pathways, now live in Australian health services and Canadian hospitals.

Perth infection management medtech Cytophenix prescribed $1.3 million in pre-Seed

Perth medtech spin-out Cytophenix raised a pre-seed round above its target to advance trials and grow the team behind FloCAST, a rapid test identifying effective antibiotics, after earlier grants and accelerator programs.

CUREator+ delivers $15.7m to seven Australian BioMedTech startups tackling dementia

Government-backed CUREator+ program awards non-dilutive funding to seven Australian companies developing dementia and cognitive decline therapeutics, devices and digital health tools.

Peter Beattie AC appointed Brandon BioCatalyst Chair

Brandon BioCatalyst has named Peter Beattie its chair as Bill Ferris retires, with Andrew Nash joining the board and Ross King becoming deputy; manager Brandon Capital's newly raised $439 million fund was noted.

Mirugen Secures A$4.5m to Pioneer Cell (Re)programming, and Welcomes Charlotte Casebourne Stock as Executive Chair

Mirugen, a Melbourne biotech spun out of an eye research institute, has closed a A$4.5m seed round with three backers and hired Charlotte Casebourne Stock as chair and acting chief executive.

Also cera.org.au·Brandon BioCatalyst portfolio·insightnews.com.au

Brandon Capital closes $439m fund with $150m leg up from the NRFC

Australia's NRFC has injected $150m into Brandon Capital's sixth life-science vehicle, lifting it to a $439m close; past NRFC cheques to local deep-tech firms are also recapped.

PolyActiva Secures $40M in Series C Financing to Advance Innovation in Sustained Ocular Drug Delivery

Australian biotech PolyActiva has raised A$40 million in Series C funding to advance its PA5108 ocular implant and PREZIA platform, backed by the National Reconstruction Fund Corporation and Brandon Capital.

Also Brandon Capital portfolio·Brandon BioCatalyst portfolio·SmartCompany·SmartCompany·polyactiva.com·Startup Daily·ophthalmologybreakingnews.com·Forbes Australia

CUREator+ Opens Second Funding Round Offering Up to $5M for Dementia BioMedTech Startups

CUREator+, backed by Brandon BioCatalyst, ANDHealth and Dementia Australia, launches second round offering non-dilutive funding to startups targeting dementia and cognitive decline.

Meet Proxima Bio: Australia's next-generation biotech startup aiming to clean up cancer-causing proteins.

Profile of Australian biotech startup Proxima Bio, covering its founding, an early MRFF grant through the CUREator program, Brandon Capital's guidance, and a later larger investment that grew the team.

Vaxxas Named Stage Winner of United States' BARDA Prize to Advance Microarray Patches for Vaccination

Vaxxas wins US$2 million as a concept-stage winner of BARDA's prize to advance its skin-patch vaccine platform with UQ's BASE facility; the article also recalls early backing by OneVentures, Brandon Capital and HealthCare Ventures.

Also Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·@AuManufacturing·@AuManufacturing·Business News Australia

CUREator+ Deploys $18.5 million in its First Funding Round

Eight Australian health startups received equity-free grants totaling 18.5 million dollars from the CUREator+ program, supported by government funding and delivered with partners Brandon BioCatalyst and ANDHealth.

Brandon BioCatalyst’s CUREator Incubator Boosts Preclinical and Health Security Biotech Innovations with $1.865m in funding.

Brandon BioCatalyst's CUREator incubator has granted an extra $1.865m across four Australian biotechs working on antibiotic prescribing, schizophrenia, muscular dystrophy and autoimmune therapies, on top of their initial awards.

CUREator+ opens first funding round for dementia innovations with up to $5 million per project

The CUREator+ incubator, backed by government funds and industry partners, launches its initial grant round offering non-dilutive capital to startups developing dementia and cognitive decline solutions.

Funding Australia’s Future Economy: CUREator Deploys $7.21 Million to Propel local Life Sciences Potential

CUREator, Brandon BioCatalyst's government-backed grant program, has awarded $7.21 million across eight Australian biotech firms in its newest round, split between clinical-stage and preclinical recipients.

Also Brandon BioCatalyst portfolio·Startup Daily·ausceleratesa.org

$3 million awarded to five antimicrobial resistance-related projects

Brandon BioCatalyst's CUREator biotech incubator has allocated $3 million across five antimicrobial resistance projects, with a UWA-linked nasal spray venture, Spritz-OM, receiving $500,000 toward Phase 1 clinical trials.

Vaxxas Announces and Publishes Successful Phase I Clinical Trial for Measles and Rubella Vaccine Delivered Using its Proprietary High-Density Microarray Skin Patch; Plan for Phase I/II Trial in The Gambia, Africa

Vaxxas reports positive Phase I results for its needle-free skin-patch delivery of a measles-rubella vaccine, with Gates Foundation grant funding and a planned PATH-sponsored Phase I/II trial in The Gambia.

Cicada Innovations to launch new health-focused hub in Westmead Health Precinct alongside Brandon BioCatalyst

Cicada Innovations is opening a health-tech incubator at Sydney's Westmead precinct with NSW government grant backing, working with Brandon Capital and Brandon BioCatalyst to help researchers commercialise medical discoveries.

Cicada Innovations to launch new health-focused hub in Westmead Health Precinct alongside Brandon BioCatalyst

Deep tech incubator Cicada Innovations is opening a health-focused facility at Sydney's Westmead precinct with Investment NSW backing, working with Brandon Capital and Brandon BioCatalyst to help early medical startups commercialise.

Biotech incubator CUREator tips $12 million into 19 startups tackling global health

Biotech incubator CUREator's second round distributes $12 million among 19 health-focused startups, supported by government funding, while a new MedTech program backed by $50 million arrives later in the year.

Nineteen groundbreaking biotech projects selected for national incubator

CUREator, the national biotech incubator operated by Brandon BioCatalyst, selects 19 projects for its second funding round worth $12 million, and a $50 million MRFF award will add a MedTech stream.

EBR Systems meets endpoints early in pivotal SOLVE-CRT trial: paves way for FDA approval application and commercialisation

Cardiac pacing company EBR Systems says its SOLVE-CRT trial hit its safety and efficacy goals early, keeping a 2024 US approval bid on course; the article also recalls its 2021 ASX listing.

Also Brandon BioCatalyst portfolio

Vaxxas initiates Phase I study for needle-free seasonal influenza vaccine delivered using High-Density Microarray Patch (HD-MAP)

Vaxxas has begun an Australian Phase I trial of its needle-free influenza vaccine patch. The article also recalls the company's founding equity financing led by OneVentures with Brandon Capital Partners and other co-investors.

Vaxxas Raises US$23 million (A$34 million) to Clinically Advance Needle-Free Vaccines, Including a Next-Generation COVID-19 Vaccine Candidate

Vaxxas completed a US$23 million (A$34 million) financing led by OneVentures and UniQuest to advance its needle-free vaccine clinical programs, including a COVID-19 candidate, with board members, management and individual investors also participating.

Also OneVentures portfolio·Brandon Capital portfolio·@AuManufacturing·SmartCompany·Techboard·@AuManufacturing

QUE Oncology's non-hormonal therapy reduces hot flushes and night sweats in women with breast cancer, published in The Lancet

QUE Oncology reports its non-hormonal drug Q-122 eased hot flushes in breast cancer patients on endocrine therapy, with Phase II results in The Lancet; the Emory–UniQuest venture is backed by Brandon BioCatalyst and Uniseed.

QUE Oncology's non-hormonal therapy reduces hot flushes and night sweats in women with breast cancer, published in The Lancet

Brandon Capital's blog covers QUE Oncology's Phase II Q-122 results in The Lancet, showing reduced hot flushes and night sweats in breast cancer patients on endocrine therapy.

Vaxxas Announces Initiation of Phase I Clinical Study of First Needle-Free COVID-19 Vaccine Delivered Using High-Density Microarray Patch (HD-MAP)

Vaxxas has begun an Australian Phase I trial of its needle-free COVID-19 vaccine patch; the article also recalls the company's founding financing led by OneVentures with Brandon Capital and other co-investors.

First Aussies to get needle-free COVID-19 vaccine patch

Vaxxas has begun a phase one trial in Australia of its needle-free COVID-19 vaccine patch. The Brisbane company, backed by OneVentures, Brandon Capital and others, has hired Scott Fry from Ellume as COO.

First Aussies to get needle-free COVID-19 vaccine patch

Brisbane biotech Vaxxas has begun human testing of its microneedle patch for COVID-19 vaccination and plans a phase two study; the venture-backed company has raised over $66 million.

$16m cash injection to progress first-in-class therapy for inflammation and fibrosis

Australian biotech OccuRx secured $16 million co-led by Brandon BioCatalyst and Uniseed, including a CUREator grant, to advance its oral anti-fibrosis therapy into kidney disease trials; two executives also joined.

Also Brandon BioCatalyst portfolio·Startup Daily

Azura Ophthalmics Secures Grant to Evaluate AZR-MD-001 for Improved Vision Quality Related to Contact Lens Discomfort

Azura Ophthalmics won a CUREator grant to fund a two-stage study of its AZR-MD-001 candidate for contact lens discomfort, extending pilot research conducted with UNSW; the incubator program is run by Brandon BioCatalyst.

Also Brandon BioCatalyst portfolio

Australia’s first national biotech incubator announces round one funding to support life science breakthroughs

Brandon BioCatalyst's CUREator incubator names its first-round awardees, distributing government-backed funding across 23 Australian life science companies working on treatments from schizophrenia to diabetes, with round two applications now open.

Australia's first national biotech incubator announces round one funding to support life science breakthroughs

The CUREator incubator, run by Brandon BioCatalist's partner organisation, names its first-round awardees, distributing government-backed grant funding across 23 Australian life science companies developing treatments for diseases including diabetes, cancer and COPD.

Amaroq Therapeutics hits early milestones and makes key appointments to Scientific Advisory Board

Cancer biotech Amaroq Therapeutics appointed four experts to its advisory board as it moves toward clinical trials; the New Zealand company's backers include Brandon Capital, which reports $14m invested to date.